Usefulness of intermediate amino-terminal pro-brain natriuretic peptide concentrations for diagnosis and prognosis of acute heart failure - PubMed (original) (raw)
Comparative Study
. 2006 Aug 1;98(3):386-90.
doi: 10.1016/j.amjcard.2006.02.043. Epub 2006 Jun 12.
Affiliations
- PMID: 16860029
- DOI: 10.1016/j.amjcard.2006.02.043
Comparative Study
Usefulness of intermediate amino-terminal pro-brain natriuretic peptide concentrations for diagnosis and prognosis of acute heart failure
Roland R J van Kimmenade et al. Am J Cardiol. 2006.
Abstract
Age-stratified cutpoints for aminoterminal pro-brain natriuretic peptide (NT-pro-BNP) concentrations are diagnostic in 83% of all subjects with acute dyspnea. This study analyzed subjects with NT-pro-BNP concentrations between the "rule-out" and "rule-in" cutpoints, the so-called natriuretic peptide gray zone. NT-pro-BNP concentrations, clinical characteristics, and 60-day mortality were studied in 1,256 acutely dyspneic patients from an international multicenter study. Of all subjects, 215 had gray-zone NT-pro-BNP concentrations, 116 of whom (54%) were diagnosed with heart failure (HF). Among these subjects, patients with HF were more likely to be older, to have a history of HF, to be in atrial fibrillation, and to have elevated troponin T concentrations compared with those without HF. In multivariate analysis, the use of loop diuretics on presentation (odds ratio [OR] 3.99, 95% confidence interval [CI] 1.58 to 10.1, p = 0.003), paroxysmal nocturnal dyspnea (OR 4.50, 95% CI 1.31 to 15.4, p = 0.02), jugular venous distention (OR 3.05, 95% CI = 1.06 to 8.79, p = 0.04), and the absence of cough (OR 0.18, 95% CI 0.06 to 0.52, p = 0.001) were associated with a diagnosis of acute HF in gray-zone patients. Subjects with HF and diagnostically elevated NT-pro-BNP concentrations had the highest mortality rates, subjects without HF and NT-pro-BNP concentrations < 300 ng/L had the lowest mortality rates, and subjects with gray-zone NT-pro-BNP had intermediate outcomes, irrespective of their final diagnoses. Adding specific clinical information to NT-pro-BNP improves diagnostic accuracy in subjects with intermediate NT-pro-BNP concentrations. Mortality rates in subjects with intermediate NT-pro-BNP concentrations are lower than in those with NT-pro-BNP concentrations diagnostic for HF but are higher than in subjects with NT-pro-BNP concentrations less than the gray zone.
Similar articles
- Usefulness of aminoterminal pro-brain natriuretic peptide testing for the diagnostic and prognostic evaluation of dyspneic patients with diabetes mellitus seen in the emergency department (from the PRIDE Study).
O'Donoghue M, Kenney P, Oestreicher E, Anwaruddin S, Baggish AL, Krauser DG, Chen A, Tung R, Cameron R, Januzzi JL Jr. O'Donoghue M, et al. Am J Cardiol. 2007 Nov 1;100(9):1336-40. doi: 10.1016/j.amjcard.2007.06.020. Epub 2007 Aug 9. Am J Cardiol. 2007. PMID: 17950786 Clinical Trial. - Comparison of prognostic significance of amino-terminal pro-brain natriuretic Peptide versus blood urea nitrogen for predicting events in patients hospitalized for heart failure.
Shenkman HJ, Zareba W, Bisognano JD. Shenkman HJ, et al. Am J Cardiol. 2007 Apr 15;99(8):1143-5. doi: 10.1016/j.amjcard.2006.11.050. Epub 2007 Mar 2. Am J Cardiol. 2007. PMID: 17437744 - Importance and interpretation of intermediate (gray zone) amino-terminal pro-B-type natriuretic peptide concentrations.
van Kimmenade RR, Pinto YM, Januzzi JL Jr. van Kimmenade RR, et al. Am J Cardiol. 2008 Feb 4;101(3A):39-42. doi: 10.1016/j.amjcard.2007.11.018. Am J Cardiol. 2008. PMID: 18243857 Review. - Amino-terminal pro-B-type natriuretic peptide testing for the diagnosis or exclusion of heart failure in patients with acute symptoms.
Januzzi JL Jr, Chen-Tournoux AA, Moe G. Januzzi JL Jr, et al. Am J Cardiol. 2008 Feb 4;101(3A):29-38. doi: 10.1016/j.amjcard.2007.11.017. Am J Cardiol. 2008. PMID: 18243855 Review.
Cited by
- Unveiling the Role of Biomarkers in Cardiovascular Risk Assessment and Prognosis.
Bhatnagar S, Jain M. Bhatnagar S, et al. Cureus. 2024 Jan 8;16(1):e51874. doi: 10.7759/cureus.51874. eCollection 2024 Jan. Cureus. 2024. PMID: 38327929 Free PMC article. Review. - Management of Acute Heart Failure during an Early Phase.
Takagi K, Kimmoun A, Sato N, Mebazaa A. Takagi K, et al. Int J Heart Fail. 2020 Apr 17;2(2):91-110. doi: 10.36628/ijhf.2019.0014. eCollection 2020 Apr. Int J Heart Fail. 2020. PMID: 36263292 Free PMC article. Review. - Incidence of Preclinical Heart Failure in a Community Population.
Young KA, Scott CG, Rodeheffer RJ, Chen HH. Young KA, et al. J Am Heart Assoc. 2022 Aug 2;11(15):e025519. doi: 10.1161/JAHA.122.025519. Epub 2022 Jul 20. J Am Heart Assoc. 2022. PMID: 35862175 Free PMC article. - High sensitivity Troponins In Patients with elevated prohormone of beta natriuretic peptide and acute heart failure (HIGH TRIP Trial).
Alhejily WA. Alhejily WA. Sci Rep. 2022 Feb 3;12(1):1838. doi: 10.1038/s41598-022-05759-x. Sci Rep. 2022. PMID: 35115590 Free PMC article. - N-terminal prohormone B-type natriuretic peptide variability acts as a predictor of poor prognosis in patients with cardiorenal syndrome type 2.
Ma M, Luo Q, Dong X, Cui S, Hocher B, Zeng S, Liang W, Li Q, Chen X, Chen X, Meng Y, Lu Y, Yang D, Yin L. Ma M, et al. Bioengineered. 2021 Dec;12(2):12407-12419. doi: 10.1080/21655979.2021.2005219. Bioengineered. 2021. PMID: 34905428 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous